169 related articles for article (PubMed ID: 31445538)
1. Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice.
Almeida A; Pierdomenico F; Guerrero BP; Saraiva F; Montalvão A; Coutinho J; Mariz M; Melo T; Santos MJ; Pereira A; Cerveira N
Acta Med Port; 2019 Aug; 32(7-8):550-557. PubMed ID: 31445538
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Rea D; Ame S; Berger M; Cayuela JM; Charbonnier A; Coiteux V; Cony-Makhoul P; Dubruille V; Dulucq S; Etienne G; Legros L; Nicolini F; Roche-Lestienne C; Escoffre-Barbe M; Gardembas M; Guerci-Bresler A; Johnson-Ansah H; Rigal-Huguet F; Rousselot P; Mahon FX;
Cancer; 2018 Jul; 124(14):2956-2963. PubMed ID: 29723417
[TBL] [Abstract][Full Text] [Related]
3. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.
Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691
[TBL] [Abstract][Full Text] [Related]
4. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Breccia M; Foà R
Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
[TBL] [Abstract][Full Text] [Related]
5. The concept of treatment-free remission in chronic myeloid leukemia.
Saußele S; Richter J; Hochhaus A; Mahon FX
Leukemia; 2016 Aug; 30(8):1638-47. PubMed ID: 27133824
[TBL] [Abstract][Full Text] [Related]
6. The story of tyrosine kinase inhibitors discontinuation in clinical practice.
Rousselot P
Leuk Lymphoma; 2018 Dec; 59(12):2782-2791. PubMed ID: 29909726
[TBL] [Abstract][Full Text] [Related]
7. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
8. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
9. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
[TBL] [Abstract][Full Text] [Related]
11. Treatment-free remission in patients with chronic myeloid leukaemia.
Ross DM; Hughes TP
Nat Rev Clin Oncol; 2020 Aug; 17(8):493-503. PubMed ID: 32377005
[TBL] [Abstract][Full Text] [Related]
12. Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia.
Goldberg SL; Savona M; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):98-105. PubMed ID: 29274688
[TBL] [Abstract][Full Text] [Related]
13. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
14. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
15. Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?
Eşkazan AE
Br J Clin Pharmacol; 2018 Aug; 84(8):1635-1638. PubMed ID: 29862545
[No Abstract] [Full Text] [Related]
16. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
17. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
18. Response to Therapy, Treatment Intolerance and Tyrosine Kinase Inhibitor Cessation Eligibility in a Real-World Cohort of Chronic Myeloid Leukaemia Patients.
McMullan RR; McConville C; McMullin MF
Ulster Med J; 2019 May; 88(2):105-110. PubMed ID: 31061559
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression.
Rivano M; Cancanelli L; Zovi A; Addis C; Mengato D; Chiumente M; Messori A
J Chemother; 2020 Sep; 32(5):268-271. PubMed ID: 31984876
[No Abstract] [Full Text] [Related]
20. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]